The global smoking cessation and nicotine de-addiction products market revenue was around US$ 22.1 billion in 2022 and is estimated to reach US$ 54.7 billion by 2031, growing at a compound annual growth rate (CAGR) of 10.6% during the forecast period from 2023 to 2031.
Smoking cessation or nicotine de-addiction includes tobacco discontinuation. Nicotine which is present in tobacco and known to promote addiction, releases neurotransmitters like glutamate, gamma-aminobutyric acid (GABA), and dopamine. Smoking cessation products are highly profitable in treating tobacco and cigarette addicts.
Market Driving Factors
Numerous anti-smoking initiatives are organized by governments to overcome this issue, which further raises public awareness of the benefits of quitting smoking. In addition, increase in smokers, smoking-related respiratory diseases, public anti-smoking efforts, and increased awareness of smoking cessation therapies. Therefore, such factors contribute to driving the market growth.
Rising demand for smoking cessation products and e-cigarettes boosts the market growth. Many tobacco consumers are quitting tobacco and smoking habit due to the negative impact of tobacco products on human health. Therefore, an increasing number of people who want to quit their tobacco habit aids in increasing smoking cessation and nicotine de-addiction products.
The surge in the number of technical failures in products may restrain the market.
Regional Analysis
Asia-Pacific is estimated to dominate the market. This is due to the increasing number of populations who are quitting smoking. In addition, various organizations, such as NGOs and governments worldwide are creating awareness programs, which drive the market growth. Furthermore, change in the youth towards e-cigarettes, authorized smoking cessation medicines, and increased investment of key players in research and development. Thus, these elements propel the market growth.
North America dominates the market over the forecast period. This is due to the existence of essential players, well-developed healthcare infrastructure, the surge in government initiatives, and an increase in the prevalence of bacterial and viral-related infectious diseases in the region.
Segmentation Insights
Product Insight
The e-cigarette segment is expected to be the fastest-growing in the market over the projection period. The surge in popularity of e-cigarettes supported by their electronic feature is considered to be the main element contributing to its rising demand. For instance, companies like NJOY are now producing e-cigarette devices with a handy recharging feature. In line with this, Vapor Corp, VMR Products LLC, and Lorillard Inc. are a few of the major companies that produce e-cigarettes.
The nicotine replacement therapy products segment dominated the market and is estimated to continue its dominance. This can be attributed to the ease of use, greater accessibility, and its effectiveness in lowering the nicotine craving in smokers.
Form Insight
The gum segment dominated the market. This can be attributed to the increase in the demand for nicotine replacement therapy products and the surge in awareness about quitting smoking.
Distribution Channel Insight
The online providers segment is estimated to increase at the highest CAGR during the projection period. This is due to the increase in digitalization, faster delivery of products, ease of purchase, and accessibility of smartphones.
Prominent Companies
Segmentation Outline
The global smoking cessation and nicotine de-addiction products market segmentation focuses on Product, Form, Distribution Channel, and Region.
By Product
By Form
By Distribution Channel
By Region
[TABLE OF CONTENTS]
1 INTRODUCTION OF GLOBAL SMOKING CESSATION AND NICOTINE DE-ADDICTION PRODUCTS MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY: SMOKING CESSATION AND NICOTINE DE-ADDICTION PRODUCTS MARKET
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
3.5 ANALYST TOOLS AND MODELS
4 GLOBAL SMOKING CESSATION AND NICOTINE DE-ADDICTION PRODUCTS MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS AND TRENDS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE ANALYSIS
4.4 VALUE CHAIN ANALYSIS
4.5 MARKET GROWTH AND OUTLOOK
4.5.1 PRICE TREND ANALYSIS
4.5.2 OPPORTUNITY SHARE
5 GLOBAL SMOKING CESSATION AND NICOTINE DE-ADDICTION PRODUCTS MARKET, BY PRODUCT
5.1 OVERVIEW
5.2 NICOTINE REPLACEMENT THERAPY PRODUCTS
5.2.1 NICOTINE LOZENGES
5.2.2 NICOTINE GUMS
5.2.3 NICOTINE SPRAYS
5.2.4 NICOTINE INHALERS
5.3 DRUG THERAPY
5.4 E-CIGARETTES
6 GLOBAL SMOKING CESSATION AND NICOTINE DE-ADDICTION PRODUCTS MARKET, BY FORM
6.1 OVERVIEW
6.2 GUM
6.3 INHALER
6.4 TABLET
6.5 OTHERS
7 GLOBAL SMOKING CESSATION AND NICOTINE DE-ADDICTION PRODUCTS MARKET, BY DISTRIBUTION CHANNEL
7.1 OVERVIEW
7.2 HOSPITAL PHARMACIES
7.3 ONLINE PROVIDER
7.4 DRUG STORES AND RETAIL PHARMACIES
8 GLOBAL SMOKING CESSATION AND NICOTINE DE-ADDICTION PRODUCTS MARKET, BY GEOGRAPHY
8.1 OVERVIEW
8.2 NORTH AMERICA
8.2.1 NORTH AMERICA MARKET SNAPSHOT
8.2.2 U.S.
8.2.3 CANADA
8.2.4 MEXICO
8.3 EUROPE
8.3.1 EUROPE MARKET SNAPSHOT
8.3.2 WESTERN EUROPE
8.3.2.1 THE UK
8.3.2.2 GERMANY
8.3.2.3 FRANCE
8.3.2.4 ITALY
8.3.2.5 SPAIN
8.3.2.6 REST OF WESTERN EUROPE
8.3.3 EASTERN EUROPE
8.3.3.1 POLAND
8.3.3.2 RUSSIA
8.3.3.3 REST OF EASTERN EUROPE
8.4 ASIA PACIFIC
8.4.1 ASIA PACIFIC MARKET SNAPSHOT
8.4.2 CHINA
8.4.3 JAPAN
8.4.4 INDIA
8.4.5 AUSTRALIA & NEW ZEALAND
8.4.6 ASEAN
8.4.7 REST OF ASIA PACIFIC
8.5 MIDDLE EAST & AFRICA
8.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
8.5.2 UAE
8.5.3 SAUDI ARABIA
8.5.4 SOUTH AFRICA
8.5.5 REST OF MEA
8.6 SOUTH AMERICA
8.6.1 SOUTH AMERICA MARKET SNAPSHOT
8.6.2 BRAZIL
8.6.3 ARGENTINA
8.6.4 REST OF SOUTH AMERICA
9 GLOBAL SMOKING CESSATION AND NICOTINE DE-ADDICTION PRODUCTS MARKET COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 COMPANY MARKET RANKING
9.3 KEY DEVELOPMENT STRATEGIES
9.4 COMPETITIVE DASHBOARD
9.5 PRODUCT MAPPING
9.6 TOP PLAYER POSITIONING, 2022
9.7 COMPETITIVE HEATMAP
9.8 TOP WINNING STRATEGIES
10 COMPANY PROFILES
10.1 PFIZER INC
10.1.1 OVERVIEW
10.1.2 FINANCIAL PERFORMANCE
10.1.3 PRODUCT OUTLOOK
10.1.4 KEY DEVELOPMENTS
10.1.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.2 BRITISH AMERICAN TOBACCO PLC
10.2.1 OVERVIEW
10.2.2 FINANCIAL PERFORMANCE
10.2.3 PRODUCT OUTLOOK
10.2.4 KEY DEVELOPMENTS
10.2.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.3 ZYDUS CADILA INC
10.3.1 OVERVIEW
10.3.2 FINANCIAL PERFORMANCE
10.3.3 PRODUCT OUTLOOK
10.3.4 KEY DEVELOPMENTS
10.3.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.4 PERRIGO COMPANY PLC
10.4.1 OVERVIEW
10.4.2 FINANCIAL PERFORMANCE
10.4.3 PRODUCT OUTLOOK
10.4.4 KEY DEVELOPMENTS
10.4.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.5 22ND CENTURY GROUP INC
10.5.1 OVERVIEW
10.5.2 FINANCIAL PERFORMANCE
10.5.3 PRODUCT OUTLOOK
10.5.4 KEY DEVELOPMENTS
10.5.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.6 NJOY COMPANY
10.6.1 OVERVIEW
10.6.2 FINANCIAL PERFORMANCE
10.6.3 PRODUCT OUTLOOK
10.6.4 KEY DEVELOPMENTS
10.6.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.7 DR. REDDY’S LABORATORIES LTD
10.7.1 OVERVIEW
10.7.2 FINANCIAL PERFORMANCE
10.7.3 PRODUCT OUTLOOK
10.7.4 KEY DEVELOPMENTS
10.7.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.8 GLAXOSMITHKLINE PLC
10.8.1 OVERVIEW
10.8.2 FINANCIAL PERFORMANCE
10.8.3 PRODUCT OUTLOOK
10.8.4 KEY DEVELOPMENTS
10.8.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.9 IMPERIAL BRANDS PLC
10.9.1 OVERVIEW
10.9.2 FINANCIAL PERFORMANCE
10.9.3 PRODUCT OUTLOOK
10.9.4 KEY DEVELOPMENTS
10.9.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.10 JOHNSON AND JOHNSON INC
10.10.1 OVERVIEW
10.10.2 FINANCIAL PERFORMANCE
10.10.3 PRODUCT OUTLOOK
10.10.4 KEY DEVELOPMENTS
10.10.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.11 RUSAN PHARMA LTD
10.11.1 OVERVIEW
10.11.2 FINANCIAL PERFORMANCE
10.11.3 PRODUCT OUTLOOK
10.11.4 KEY DEVELOPMENTS
10.11.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.12 CIPLA LTD
10.12.1 OVERVIEW
10.12.2 FINANCIAL PERFORMANCE
10.12.3 PRODUCT OUTLOOK
10.12.4 KEY DEVELOPMENTS
10.12.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
著作権 ©2022 無断複写・転載を禁じます